⌕
Erasca · ERAS · Nasdaq
Tenet 51 · Mixed
Compare
$15.66−0.76%At closeTenet 51 · Mixed
$15.66−0.12 (−0.76%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Erasca (ERAS) Stock

Erasca (ERAS) closed at $15.66 on Nov 13, 2026; its Tenet Score is 51 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

30 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$15.66
Nov 13, 2026
Market cap
$5.5B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
2.46 – 24.28
low → high
Tenet Score
51/100
Mixed · 409 Healthcare peers

Industry: Health Services · see every company filed here →

Erasca Inc scores 51/100. Mixed. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 51 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
51/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
35
Quality
26
Health
91
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueDQualityFHealthAGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
loss
P/B
6.0×
price to book value
P/S
—
no P/S on file
ROE
−49%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
pre_revenue
Current ratio
14.89
current assets to liabilities
Net debt / EBITDA
—
no_ebitda
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Erasca Inc

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for th…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 79 US ETFs · top wrappers by weightSee all ETFs holding ERAS →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Erasca in?

Erasca is in the Healthcare sector and the Health Services industry.

What is Erasca's Tenet Score?

Erasca's Tenet Score is 51 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.